Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBIT: 2015-2025

Historic EBIT for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$22.5 million.

  • Seres Therapeutics' EBIT rose 22.94% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.4 million, marking a year-over-year increase of 20.13%. This contributed to the annual value of -$121.3 million for FY2024, which is 37.82% up from last year.
  • Seres Therapeutics' EBIT amounted to -$22.5 million in Q3 2025, which was up 9.66% from -$24.9 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' EBIT peaked at $68.4 million during Q3 2021, and registered a low of -$70.6 million during Q1 2023.
  • Over the past 3 years, Seres Therapeutics' median EBIT value was -$28.9 million (recorded in 2024), while the average stood at -$27.1 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 328.06% in 2021, then slumped by 2,038.88% in 2023.
  • Over the past 5 years, Seres Therapeutics' EBIT (Quarterly) stood at -$49.4 million in 2021, then surged by 96.50% to -$1.7 million in 2022, then crashed by 2,038.88% to -$37.0 million in 2023, then rose by 22.12% to -$28.8 million in 2024, then grew by 22.94% to -$22.5 million in 2025.
  • Its last three reported values are -$22.5 million in Q3 2025, -$24.9 million for Q2 2025, and -$27.2 million during Q1 2025.